pharmaceuticals

pharmaceuticals Articles

All three of these specialty pharmaceutical stocks come with a fair share of risk but provide big upside potential as well.
A few biohealth companies made absolutely massive runs in Thursday’s session. The companies 24/7 Wall St. has picked stood out from the rest with big moves, all at least up 10%.
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
Mylan is expected to release its second-quarter financial results after the markets close on Tuesday.
Valeant Pharmaceuticals International appears to have a turnaround underway, after the company reported its second-quarter financial results before the markets opened on Tuesday.
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.
The upcoming earnings report will showcase what Pfizer has to offer for the second half of 2016, and potentially give some insight into what companies it may be looking to pursue next.
ThinkstockShares of Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) sank on Monday after the company announced that there will be an interruption in the supply of Auryxia (ferric citrate) tablets due...
Shares of Biogen and, especially, Ionis Pharmaceuticals made handy gains early Monday morning following favorable interim results from a late-stage trial.
AbbVie released a better-than-expected second-quarter earnings report before the markets opened on Friday.
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.